|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
22 August 2016 |
|
Main ID: |
NCT02865031 |
|
Date of registration:
|
06/08/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Dacorin for Proliferative Vitreoretinopathy
Dacorin |
|
Scientific title:
|
Intravitreal Decorin Preventing Proliferative Vitreoretinopathy in Perforating Injuries: a Pilot Study. |
|
Date of first enrolment:
|
August 2015 |
|
Target sample size:
|
15 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02865031 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Countries of recruitment
|
|
Egypt
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age: > 18 years old
- Perforating Ocular Injuries zone 2 and 3.
- ERG of the affected eye was at least 50% of the unaffected fellow eye.
Exclusion Criteria:
- No concomitant ocular disease.
- No pervious ocular surgery.
- No systemic organ failure.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
PVR
|
|
Intervention(s)
|
|
Drug: Decorin
|
|
Primary Outcome(s)
|
|
Electrophysiological tests ERG a and b implicit time and latency
[Time Frame: 3 months]
|
|
Secondary Outcome(s)
|
|
Scar tissue formation graded 0-4 grades
[Time Frame: 3 months]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|